ERNA Ernexa Therapeutics Inc.
$1.99▲ +2.84%
Healthcare
Other
Volume 7.4K
Avg Volume (10D) 18.3K
Key Metrics & Fundamentals
Market Cap
$3.25M
P/E Ratio
0.0
Div Yield
0.00%
52W Range
1.84 - 71.50
% vs 50 MA
-42.21%
% vs 200 MA
-74.44%
RSI-14
30.0
MACD Histogram
+0.0400
Beta (1Y vs SPY)
0.55
Free Cash Flow
-$4.16M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$4.10M
COGS
–
Operating Exp
$4.10M
Operating Income
-$4.10M
EBIT
-$4.10M
Pretax Income
-$4.01M
Net Income
-$4.01M
EPS (Diluted)
-3.40
Price & Volume History
Loading chart…
Recent News
Ernexa Therapeutics Highlights ERNA-101’s Path Toward the Clinic and Differentiated Cell Therapy Platform in New “What This Means” Segment
GlobeNewswire · Oct 22, 2026 8:53 AM ET
Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
GlobeNewswire · Oct 12, 2026 4:05 PM ET
Ernexa Therapeutics’ ERNA-101 Selected for Flash Talk Presentation at Nature Conferences’ Next-Generation Cancer Therapeutics Meeting Co-Hosted by MD Anderson Cancer Center
GlobeNewswire · Oct 6, 2026 8:55 AM ET
Ernexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the Clinic
GlobeNewswire · Oct 1, 2026 9:20 AM ET
Ernexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 IND
GlobeNewswire · Sep 30, 2026 8:32 AM ET
Ernexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology Strategy
GlobeNewswire · Sep 29, 2026 9:15 AM ET
Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors
GlobeNewswire · Sep 17, 2026 8:42 AM ET
Ernexa Therapeutics Reports Positive Disease Modifying ERNA-201 Preclinical Data, Reinforcing iMSC Platform as Company Accelerates Oncology Strategy and ERNA-101 Toward First-in-Human Dosing
GlobeNewswire · Sep 15, 2026 8:42 AM ET
Ernexa Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · Sep 14, 2026 9:05 AM ET
Ernexa Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
GlobeNewswire · Aug 27, 2026 9:01 AM ET
Financial Overview - Income Statement
Quarterly
Dec 2024
See ERNA's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.